[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650342":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":26,"responsibleParty":43,"collaborators":26,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":26,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":26,"maxAge":26,"enrollmentInfo":55,"targetDuration":26,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":74,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":26},{"fullName":5,"class":6},"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Terlipressin Group","EXPERIMENTAL","Subcapsular injection of 1 mg terlipressin diluted in 40 mL normal saline, administered prior to fibroid enucleation during myomectomy",[13],"Drug: terlipressin (vasoconstrictor)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","Subcapsular injection of 40 mL normal saline (no active drug), administered prior to fibroid enucleation during myomectomy",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","terlipressin (vasoconstrictor)","Terlipressin 1 mg diluted in 40 mL normal saline, administered as a single subcapsular injection prior to fibroid enucleation",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","40 mL normal saline, administered as a single subcapsular injection prior to fibroid enucleation",[15],[32],{"name":33,"affiliation":5,"role":34},"Sevil Çankaya, MD","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+90 505 866 34 09","sevilsaltek82@gmail.com",{"name":41,"role":37,"phone":26,"phoneExt":26,"email":42},"Ahmet Kale, MD","ahmetkale5@gmail.com",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Sevil Cankaya","Obstetrics and Gynecology Specialist","100650342","terlipressin-vs-placebo-to-reduce-bleeding-in-fibroid-surgery-100650342",false,"NCT07746349","Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery","Efficacy of Subcapsular Diluted Terlipressin Versus Placebo in Reducing Intraoperative Blood Loss During Myomectomy: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Symptomatic uterine fibroid(s) with an indication for myomectomy, including menorrhagia, pelvic pain\u002Fpressure, or infertility\n* Largest myoma diameter between 4 and 10 cm\n* Baseline hemoglobin ≥ 9 g\u002FdL\n* Not pregnant at the time of enrollment\n* Negative urine pregnancy test or last menstrual period within 4 weeks\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* History of bleeding disorders or coagulopathy\n* Current anticoagulant or antiplatelet therapy\n* Known hypersensitivity or contraindication to terlipressin\n* Uncontrolled hypertension\n* Severe cardiac arrhythmia\n* Uncontrolled ischemic heart disease\n* Peripheral vascular disease\n* Pregnancy or suspected pregnancy\n* Previous myomectomy\n* Concurrent pelvic pathology requiring additional surgical intervention\n* Treatment with a GnRH agonist or ulipristal acetate within the 3 months preceding surgery\n* Suspected uterine malignancy, such as leiomyosarcoma\n* Inability to understand or provide informed consent","FEMALE",{"count":56,"type":57},80,"ESTIMATED","INTERVENTIONAL",[60],"NA","A myomectomy is a surgery to remove noncancerous growths (fibroids) from the uterus while keeping the uterus in place. This surgery can cause significant blood loss. Terlipressin is a medicine that narrows blood vessels and may help reduce bleeding.\n\nThis study will test whether injecting a diluted terlipressin solution under the outer covering of the fibroid, before it is removed, reduces the amount of blood lost during surgery, compared to an inactive solution (placebo). Women scheduled for myomectomy will be randomly assigned to receive either terlipressin or placebo. Neither the patients nor the surgical team will know which one was given until the study is finished. The main question this study will answer is how much blood is lost during surgery in each group.",[63,64,65],"Uterine Fibroids (Leiomyoma)","Uterine Myoma","Leiomyoma",[67,68,69,70,71,72,73],"Terlipressin","Myomectomy","Uterine Fibroids","Subcapsular Injection","Intraoperative Blood Loss","Vasopressin Analog","Placebo-Controlled Trial","NOT_YET_RECRUITING","2026-07-31",{"date":77,"type":78},"2026-08-05","ACTUAL",{"date":80,"type":57},"2026-08-01",{"date":82,"type":57},"2027-01",{"name":45,"class":6}]